The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma

A. Engert, E. A. Sausville, E. Vitetta

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.

Original languageEnglish (US)
Pages (from-to)13-33
Number of pages21
JournalCurrent Topics in Microbiology and Immunology
Volume234
StatePublished - 1998

Fingerprint

Ricin
Immunotoxins
Lymphoma
Leukemia
Hypoalbuminemia
Neoplasms
Phase II Clinical Trials
Clinical Trials, Phase I
Rhabdomyolysis
Muscle Hypotonia
Myalgia
Pulmonary Edema
Tumor Burden
Fatigue
Animal Models
Clone Cells
Sodium
Clinical Trials
Antigens
Recurrence

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Microbiology

Cite this

The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. / Engert, A.; Sausville, E. A.; Vitetta, E.

In: Current Topics in Microbiology and Immunology, Vol. 234, 1998, p. 13-33.

Research output: Contribution to journalArticle

@article{4138622117f74a92822bfcc6267a5083,
title = "The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma",
abstract = "Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.",
author = "A. Engert and Sausville, {E. A.} and E. Vitetta",
year = "1998",
language = "English (US)",
volume = "234",
pages = "13--33",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma

AU - Engert, A.

AU - Sausville, E. A.

AU - Vitetta, E.

PY - 1998

Y1 - 1998

N2 - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.

AB - Since MRD is the major cause for relapses of malignant diseases, strategies utilizing ITs to target tumor cells surviving conventional treatment have attracted scientific and clinical interest. Many different ITs against various blood-borne as well as solid malignancies have demonstrated specific potent anti-tumor effects in vitro and in animal models. Some of these have already undergone clinical phase I/II trials. The dose-limiting toxicities of RTA ITs include manifestation of VLS presenting as decreased urinary sodium excretion, hypoalbuminemia, fatigue, hypotonia, myalgia, pulmonary edema, or rhabdomyolysis. Problems encountered clinically include the development of HAMA, HARA, and HACA and the selection of antigen- deficient malignant clones. Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration.

UR - http://www.scopus.com/inward/record.url?scp=0031838566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031838566&partnerID=8YFLogxK

M3 - Article

VL - 234

SP - 13

EP - 33

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

ER -